trifarotene

01/01/2020 - "In this 52-week study, trifarotene was safe, well tolerated and effective in moderate facial and truncal acne."
01/01/2021 - "Trifarotene is effective and safe for treatment of facial and truncal acne. "
03/01/2020 - "Future studies will be required to evaluate the comparative efficacy of trifarotene 50 μg/g cream against other treatments for acne."
06/01/2022 - "Advances in Topical Management of Adolescent Facial and Truncal Acne: A Phase 3 Pooled Analysis of Safety and Efficacy of Trifarotene 0.005% Cream."
01/01/2021 - "Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris."

12/01/2023 - "At week 24, a statistically significantly greater reduction in the mean absolute change from baseline in the total atrophic scar count was noted in the trifarotene- vs vehicle-treated area (- 5.9 vs - 2.7; p < 0.0001) with differences between sides noted as early as week 2 (- 1.5 vs - 0.7; p = 0.0072). "
12/01/2023 - "Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study."
12/01/2023 - "Trifarotene was effective and well tolerated in treating moderate-to-severe facial acne and reducing atrophic acne scars, with reduction of total atrophic scar count as early as week 2. Clinicaltrials.gov NCT04856904."
12/01/2023 - "In this randomized, split-face, double-blind study, subjects (age: 17-34 years, N = 121) with moderate-to-severe facial acne, with acne scars present, were treated with either trifarotene 50 μg/g or vehicle once daily for 24 weeks. "
05/01/2023 - "10 patients between 19 and 25 years (3 males and 7 females) with previous moderate to severe acne vulgaris on the face with the outcome of atrophic and post-inflammatory slightly hyperpigmented scars were prescribed home short contact therapy (SCT) with topical trifarotene 50 &mu;g/g at the evening for 3 months. "

02/26/2021 - "Randomized trials evaluating trifarotene tolerability, safety, and efficacy in congenital ichthyosis and acne have demonstrated great results and mild side effects, leading to the approval by the FDA of trifarotene for the treatment of lamellar ichthyosis in 2014, and of acne vulgaris in October 2019. "

02/26/2021 - "No high-quality randomized clinical trials have evaluated the treatment of primary cutaneous lymphomas with trifarotene. "

02/26/2021 - "Randomized trials evaluating trifarotene tolerability, safety, and efficacy in congenital ichthyosis and acne have demonstrated great results and mild side effects, leading to the approval by the FDA of trifarotene for the treatment of lamellar ichthyosis in 2014, and of acne vulgaris in October 2019. "